In that trial, despite no notable changes in the levels or phenotype of circulating CD4+ and CD8+ T cells in peripheral blood, the administration of IFN-γ-matured DEXs increased NK cell activity in NSCLC patients after chemotherapy cessation. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.